Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled, Double-blind Evaluation of Safety, Tolerability, and Efficacy of XT- 150 for the Treatment of Facet Joint Osteoarthritis Pain

NCT05196919 is registered in ClinicalTrials.gov with Xalud Therapeutics, Inc. as lead sponsor.

NCT NCT05196919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05196919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled, Double-blind Evaluation of Safety, Tolerability, and Efficacy of XT- 150 for the Treatment of Facet Joint Osteoarthritis Pain
Lead sponsor
Xalud Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2022
Completion date
September 20, 2023
Enrollment
75 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

back pain, facet joint pain, inflammation